September 10th 2025
The FDA has assigned a Prescription Drug User Fee Act date of July 11, 2026, for relacorilant as a treatment for platinum-resistant ovarian cancer.
September 4th 2025
Genetic Analysis May Offer New Approach to Treating Ovarian Cancer
February 21st 2017California researchers are now suggesting that analyzing copies of genes may point to new treatments for ovarian cancer as well as for other tumor types. The researchers contend that targetable genetic changes in tumors should not be limited to mutations.
BRCA Reversion Mutations in cfDNA Can Predict Response in Ovarian Cancer
February 14th 2017A small study found that it is feasible to detect BRCA1/2 reversion mutations in circulating cell-free DNA in patients with recurrent high-grade serous ovarian cancer. Those reversion mutations can help predict poor response to therapy in these patients.
Endometrioid Ovarian Cancer Presents Earlier, Offers Better Survival Than Serous Carcinoma
January 20th 2017Women with endometrioid ovarian cancer present at a younger age and with earlier stage disease than those with serous ovarian cancer, according to a new analysis. The earlier presentation resulted in better 5- and 10-year overall survival rates as well.
VCAM-1 Expression Linked to Poor Survival in Epithelial Ovarian Cancer
November 24th 2016Expression of mesothelium vascular cell adhesion molecule-1 (VCAM-1) is associated with poorer overall and progression-free survival in patients with epithelial ovarian cancer, according to a retrospective analysis.
Novel WEE1 Inhibitor Increases Chemotherapy Efficacy in Ovarian Cancer
November 3rd 2016Adding the WEE1 inhibitor AZD1775 to carboplatin offered enhanced response rates in women with TP53-mutated ovarian cancer that was refractory or resistant to first-line platinum-based therapy in a phase II study.
Seribantumab Fails to Improve PFS in Ovarian Cancer; Some Patients May Benefit
October 27th 2016Adding seribantumab to paclitaxel failed to improved progression-free survival in unselected patients with platinum-resistant or -refractory ovarian cancer. Expression of heregulin and HER2, however, could identify a subset of patients that derive benefit from the therapy.
Rucaparib Demonstrates Strong Activity in BRCA-Mutated Advanced Ovarian Cancer
October 18th 2016The oral PARP inhibitor rucaparib showed strong activity and an acceptable safety profile in women with high-grade, BRCA-mutated ovarian carcinoma who had previously received at least two lines of chemotherapy.
Does Surveillance With CA-125 in Ovarian Cancer Benefit Patients?
September 22nd 2016In this Medical News Minute, developed exclusively for Cancer Network, Dr. Bobby Lazzara discusses a recent study that found that surveillance with CA-125 in ovarian cancer patients led to more use of chemotherapy, decreased quality of life, and no improvement in survival.
ACR Appropriateness Criteria® Adjuvant Management of Early-Stage Endometrial Cancer
After a review of the published literature, the panel voted on three variants to establish best practices for the utilization of imaging, radiotherapy, and chemotherapy after primary surgery for early-stage endometrial cancer.